Sirius Medical Archives - Medical Design Sourcing

Sirius Medical raises nearly $5m to commercialize non-radioactive tumor localization system

Sirius Medical has raised €4.4 million ($4.9 million) as it seeks to commercialize its Sirius Pintuition non-radioactive tumor localization system.

News of the money raise comes about a month after the Eindhoven, the Netherlands-based Sirius announced that it had won a CE Mark for the system. FDA clearance is pending.

The Series A round was led by BOM Brabant Ventures, with co-investors Curie Capital and Holland Capital. Additional funding came from the Dutch Research Council (NWO) and the Mibiton Foundation, plus local development agencies, business angels, management and existing shareholders of Sirius.

“We are grateful for the trust provided by our investors in the Sirius Medical team. The A-round funding enables Sirius Medical to execute on its ambitious growth plans; delivering superior localization technology to our customers and developing our further pipeline of solutions,” CEO Hubert Martens said in a news release.

Sirius Medical wins CE mark for non-radioactive localization system

Sirius Medical announced that it received CE Mark approval for its Sirius Pintuition non-radioactive tumor localization system.

Eindhoven, the Netherlands-based Sirius said in a news release that it intends to launch the Pintuition system in September of this year, with the first systems currently in production. The company intends to implement the systems in hospitals in the Netherlands, the U.K. and other countries in Europe in 2020 with an eye on the U.S. in 2021.

The Pintuition system is an alternative to traditional surgical localization systems that rely on anchor wires or radioactive seeds, offering a precise, easy-to-use and affordable way to improve hospital workflow. The Pintuition seed can be placed up to 180 days before surgery to mark a target within soft tissue.

During surgery, the Pintuition reusable probe, which is compatible with metal instruments commonly used during surgery, offers real-time feedback and directional guidance to the mar…

Sirius Medical wins CE mark for non-radioactive localization system

Sirius Medical announced that it received CE Mark approval for its Sirius Pintuition non-radioactive tumor localization system.

Eindhoven, the Netherlands-based Sirius said in a news release that it intends to launch the Pintuition system in September of this year, with the first systems currently in production. The company intends to implement the systems in hospitals in the Netherlands, the U.K. and other countries in Europe in 2020 with an eye on the U.S. in 2021.

The Pintuition system is an alternative to traditional surgical localization systems that rely on anchor wires or radioactive seeds, offering a precise, easy-to-use and affordable way to improve hospital workflow. The Pintuition seed can be placed up to 180 days before surgery to mark a target within soft tissue.

During surgery, the Pintuition reusable probe, which is compatible with metal instruments commonly used during surgery, offers real-time feedback and directional guidance to the mar…